Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
  • 30

  • 6

  • 3

  • 2

  • 1

  • 1

  • 1

  • 1

  • 1

  • 1

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Country of Funder
Start Year
Active Year
Similar Projects for


DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer

Funder: National Cancer Institute

Funding period
USD 300 K
Funding amount
Project Summary/Abstract Bladder cancer causes over 165,000 annual deaths worldwide with 70,000 new cases and 16,000 deaths reported in the US. Treatment of superficial bladder cancer by resection and BCG administration is unsuccessful in 40% of cases with recurrences eventually requiring cystectomy or other aggressive therapy; new therapies are needed. The role of Epidermal Growth Factor Receptor (EGFR) in bladder cancer pathogenesis has been well established and its pathologic expression on the luminal side of uroepithelial cells in 70% of patients provides an ideal target for intravesical targeted therapy. We have previously demonstrated DTEGF?a single chain protein, encoding modified diphtheria toxin (DT) that has replaced the B-chain sequence normally enabling cell entry with that of Epidermal Growth Factor?was efficacious in a syngeneic rodent model of bladder cancer, as well as in a number of xenograph explants of human bladder cancer in nude mice. Toxicity was not observed in these murine studies, nor in a pilot study in dogs demonstrated intravesical DTEGF was well tolerated at concentrations well above those needed for efficacy. IND-enabling studies are needed for DTEGF to move into the clinical testing. While we have preclinical proof-of-concept with DTEGF, another company has demonstrated Phase II clinical proof-of-concept with an EpCAM-toxinA fusion- toxin demonstrating 40% complete response in superficial bladder cancer patients. Their work provides a proven developmental path for our EGFR targeted toxin. The present grant application proposes to optimize intravesical administration and subsequently complete IND-enabling safety studies, hold a pre-IND meeting and complete an IND application. Completion of this work would position our agent as one with a very high likelihood success to be ready for clinically testing. We anticipate DTEGF to address the unmet need of patients that fail BCG (40%) and over express EGFR (70%) and eventually become a first line therapy that will likely work with EpCAM-targeted and other therapies to benefit the majority of patients.

USD 21.4 M
Aggregated funding amount
USD 446 K
Average funding amount
Project list item
Novel recombinant BCG for immunotherapy of bladder cancer

National Cancer Institute to BORIS SHOR

USD 290,014
2018 - 2019
Project list item


USD 1,081,593
2017 - 2020
Project list item
Multi-Antigen Vaccines for the Primary and Secondary Prevention of Bladder CancerTO POP: 9/15/2017 - 3/14/2019

National Cancer Institute to CLINTON GRUBBS

USD 636,313
2017 - 2019
Project list item
Role of antigen-specific immunity in BCG therapy for bladder cancer

Bladder Cancer Advocacy Network to Niannian Ji, Robert Scott Svatek

USD 50,000
2016 - 2018
Project list item
Visible Light-Controlled Combination Strategy for Treating Nonmuscle Invasive Bladder Cancers

Congressionally Directed Medical Research Programs to Youngjae You

USD 592,000
2015 - 2016
Project list item
Synergistic Immuno-Photo-Nanotherapy for Bladder Cancer

Congressionally Directed Medical Research Programs to Brant A. Inman

USD 624,398
2015 - 2016
Project list item
Regulatory T cells in intravesical BCG therapy for non-muscle invasive bladder cancer

Japan Society for the Promotion of Science to Mitsuhiro NARITA, Eiki Hanada, 亮介 村井, Akihiro KAWAUCHI, Kazumasa OGASAWARA, Susumu KAGEYAMA, Tatsuhiro YOSHIKI

USD 45,237
2014 - 2017
Project list item
Intravesical Chitosan/IL-12 Immunotherapy for Bladder Carcinoma

National Cancer Institute to DAVID ZAHAROFF

USD 416,897
2014 - 2017
Project list item
Intravesical Docetaxel Formulation for the Treatment of Ta/T1 Stage Bladder Cancer

Canadian Institutes of Health Research to Helen Mary Burt, Donald Elliott Brooks, Martin E Gleave, Jayachandran N Kizhakkedathu, Richard Tom Liggins, Alan I So

USD 276,398
2013 - 2014
Project list item
Development of bladder cancer immunotherapy

Canadian Cancer Society to Yves Fradet, Pedro De campos lima, Hélène Larue

USD 836,290
2013 - 2018
Project list item
Androgen Receptor in Bladder Cancer

National Cancer Institute to PIYUSH AGARWAL

USD 116,050
2013 - 2014
Project list item
DT-EGF Toxic Fusion Protein for Treatment of Bladder Cancer

National Cancer Institute to MIKE GLODE

USD 149,040
2012 - 2014
Project list item
Combination chemo-siRNA gene therapy of nonmuscle-invading bladder cancer

National Center for Advancing Translational Sciences to ZE LU, JESSIE L.-S. AU

USD 344,460
2012 - 2016
Project list item
Photo-assisted targeting of immunotherapy to the bladder

National Cancer Institute to DIMITRI SIMBERG, TOMOKO HAYASHI

USD 358,565
2012 - 2016
Project list item
Molecular Targeted Photoimmunotherapy for Bladder Cancer

National Cancer Institute to PIYUSH AGARWAL

USD 3,223,364
2012 - 2018
Project list item
Multifunctional Nanoporphyrin against Bladder Cancer

Congressionally Directed Medical Research Programs to Kit S Lam

USD 2,150,147
2011 - 2012
Project list item
Intra-bladder MMC & suramin for nonmuscle-invading & locally advanced bladder ca

National Cancer Institute to ZE LU, JESSIE L.-S. AU

USD 303,226
2011 - 2016
Project list item
Novel IL-15 Superagonist Therapy for Bladder Cancer

National Cancer Institute to HING C. WONG

USD 225,279
2011 - 2013
Project list item
Immunotherapeutic strategies against non-muscle-invasive bladder cancer

Swiss National Science Foundation to Denise Nardelli Haefliger

USD 360,115
2011 - 2014
load more...